Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease (CAD).

Trial Profile

A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease (CAD).

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2018

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms ONSET-OFFSET
  • Most Recent Events

    • 10 Nov 2018 Results characterizing ticagrelor exposure-response relationship for platelet inhibition in patients with stable coronary artery disease (CAD) and a history of myocardial infarction (MI), using non-linear mixed effects modelling and simulation of two trials (NCT00528411 and NCT01225562) published in the British Journal of Clinical Pharmacology
    • 31 Aug 2018 Biomarkers information updated
    • 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top